Triostin A derived hybrid for simultaneous DNA binding and metal coordination
451
H2O) to B (MeCN/H2O, 9:1 ? 0.1% TFA). Analytical
thin-layer chromatography was performed using Merck
silica gel 60 F254 precoated aluminum plates. Visualiza-
tion was achieved with UV light (254 nm) or by dyeing
with ninhydrin (3% in ethanol).
[M ? H]?. HRMS (ESI): calcd. for C40H68BrN6O9
([M ? H]?): 855.42257, found: 855.42230.
4-Bromo-2,6-bis-([1,4,7]triazacyclononane-1-yl-methyl)-
phenol (16)
Di-tertbutoxycarbonyl-[1,4,7]triazacyclononane (BBT, 12)
A solution of ligand 15 (48 mg, 56 lmol) in TFA/
DCM = 1:1 (2 mL) was stirred at rt for 1 min. The mix-
ture was evaporated to dryness in vacuo and purified by
HPLC (preparative, 0–60% MeOH ? 0.1% TFA in
30 min, Rt = 21.61 min) to yield a yellowish solid
(21.7 mg, 85%). 1H-NMR (300 MHz, [D6]DMSO):
d = 2.80–2.87 (m, 8 H, TACN-2,20,9,90-H2), 3.06–3.15 (m,
8 H, TACN-3,30,8,80-H2), 3.43–3.51 (m, 8 H, TACN-
5,50,6,60-H2), 3.80 (s, 4 H, CH2), 7.43 (s, 2 H, Ar-H), 9.13
(s br, 4 H, NH) ppm. 13C-NMR (150 MHz, [D6]DMSO):
d = 42.8 (TACN-2,20,9,90-CH2), 43.9 (TACN-3,30,8,80-
CH2), 48.4 (TACN-5,50,6,60-CH2), 52.9 (CH2), 110.5 (Ar-
CBr), 126.9 (Ar-CCH2), 133.4 (Ar-CH), 153.9 (Ar-COH)
ppm. HRMS (ESI): calcd. for C20H35BrN6O ([M ? H]?):
455.2128, found: 455.2120.
Dry Et3N (5.18 mL, 37.1 mmol) was added to a cooled
solution (-5°C) of TACN (2.40 g, 18.6 mmol) in dry
DCM (60 mL). A solution of Boc2O (tert-butyloxycar-
bonyl anhydride, 8.10 g, 37.1 mmol) in dry DCM (20 mL)
was added over a period of 1 h and stirred for 30 min at
-5°C. All volatile components were removed in vacuo and
the residue was dissolved in MeOH/EtOAc = 1:8 and
purified by flash chromatography (4 9 18 cm, MeOH/
EtOAc = 1:8) to yield a yellow oil (3.28 g, 54%). 1H-
NMR (300 MHz, CDCl3): d = 1.45 (s, 18 H, Boc-CH3),
2.87–2.97 (m, 4 H, 2, 9-H2), 3.17–3.32 (m, 4 H, 3, 8-H2),
3.39–3.52 (m, 4 H, 5, 6-H2) ppm. MS (ESI, MeOH):
m/z (%) = 330 (100) [M ? H]?, 352 (10) [M ? Na]?.
4-Bromo-2,6-di-(bromomethyl)-phenol (14)
4-Azido-2,6-bis-(di-tertbutoxycarbonyl-
[1,4,7]triazacyclononane-1-yl-methyl)-phenol (6)
HBr in acetic acid (33 wt%, 37.0 mL, 0.21 mol) was
added to 4-bromo-2,6-dihydroxy-phenol (13, 10.0 g,
42.9 mmol) at 0°C and stirred for 20 min at 0°C. The
solution was allowed to warm to rt and was stirred for
another 24 h at rt. Water (50 mL) was added and the
precipitate was filtered off, washed with water (29
40 mL) and dried in vacuo to yield 92% (14.2 g,
39.6 mmol) of compound 14 which was used for the
synthesis of 15 without further purification.
An argon-saturated solution of ligand 15 (0.52 g, 0.60
mmol) and dimethylethylenediamine (64.9 lL, 0.60 mmol)
in EtOH/H2O = 7:3 (50 mL) was added to sodium azide
(0.12 g, 1.80 mmol), sodium ascorbate (0.36 g, 1.80 mmol)
and copper iodide (0.35 g, 1.80 mmol) and refluxed for
24 h. The mixture was filtered over silica, the filtrate
evaporated to dryness and dried in vacuo to yield a
brown-yellow solid (0.34 g, 70%). 1H-NMR (300 MHz,
[D6]DMSO, 100°C): d = 1.44 (s, 36 H, Boc-CH3),
2.66–2.77 (m, 8 H, TACN-6,60,8,80-H2), 3.24–3.31 (m, 8 H,
TACN-5,50,9,90-H2), 3.38–3.45 (m, 8 H, TACN-2,20,3,30-
H2), 3.75 (s, 4 H, CH2), 6.83 (s, 2 H, Ar-H) ppm. MS
(ESI, MeOH): m/z (%) = 818 (100) [M ? H]?, 840
(25) [M ? Na]?. HRMS (ESI): calcd. for C40H68N9O9
([M ? H]?): 818.51345, found: 818.51336.
4-Bromo-2,6-bis-(di-tertbutoxycarbonyl-
[1,4,7]triazacyclononane-1-yl-methyl)-phenol (15)
Potassium carbonate (1.01 g, 7.30 mmol) was added to a
solution of 4-bromo-2,6-bis-bromomethyl-phenol (1.25 g,
3.48 mmol), BBT 12 (2.40 g, 7.30 mmol) in dry MeCN
(25 mL) and stirred for 16 h at 60°C. The remaining solid
was separated by filtration and the filtrate evaporated to
dryness. The residue was purified by flash chromatography
(4 9 20 cm, EtOAc/pentane = 1:1) to yield a yellow solid
Cyclo[b-D-Dap(adenine-9-yl-acetyl)-L-Ala-L-Cys-L-[1-(4-
hydroxy-3,5-bis-[1,4,7]triazacyclonane-1-yl-methyl-
phenyl)-1H-[1,2,3]triazole-4-yl]-Gly-b-D-Dap
1
(2.42 g, 81%). H-NMR (300 MHz, [D6]DMSO, 100°C):
(thymine-1-yl-acetyl)-L-Ala-L-Cys-L-Val]-disulfide (4)
d = 1.44 (s, 36 H, Boc-CH3), 2.67–2.74 (m, 8 H, TACN-
6,60,8,80-H2), 3.25–3.30 (m, 8 H, TACN-5,50,9,90-H2), 3.40
(s, 8 H, TACN-2,20,3,30-H2), 3.75 (s, 4 H, CH2), 7.22 (s, 2
H, Ar-H) ppm. 13C-NMR (150 MHz, [D6]DMSO, 100°C):
d = 27.7 (Boc-CH3), 48.5 (TACN-CH2), 52.3 (TACN-
CH2), 55.4 (CH2), 78.4 (Boc-C), 109.3 (Ar-CBr), 126.0
(Ar-CCH2), 130 (Ar-CH), 154.2 (Boc-CO), 154.5
(Ar-COH) ppm. MS (ESI, MeOH): m/z (%) = 855 (100)
A solution of 2,6-lutidine in dry DMF (5 mL, 8 mM) was
saturated with argon; cyclopeptide 5 (0.5 mg, 0.4 lmol),
ligand 6 (0.9 mg, 1.1 lmol), [CuIP(OEt)3] (catalytic)
and
tris-(1-benzyl-1H-[1,2,3]triazole-4-yl-methyl)amine
(TBTA) (catalytic) were placed in a 0.5 mL Eppendorf cap
equipped with a magnetic stirrer. 2,6-Lutidine in dry DMF
(100 lL, 0.8 mmol) was added under argon. The mixture
123